Oral GCD had no treatment-induced antibodies in the 12 patients. Steadier dosage is better. Should file for FDA Breakthough Status.
inglebertney826 wrote: "Still going know where fast." Should be "nowhere" I think. In that case, you should COVER YOUR SHORT.
PLX has valuable platform and stock is a value in the biotech space. Pipeline is slow going and not too exciting on the surface.
Still going know where fast. Sell and move on folks
Still going know where fast. Sell and move on folks.